Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytokine-inducible SH2-containing protein (CISH) is a member of the suppressor of cytokine signaling (SOCS) family. It acts as an inducible inhibitor of cytokine signaling, negatively regulating T cell receptor (TCR) signaling and natural killer (NK) cell cytotoxicity. Dysregulation of CISH is linked to various diseases, including infections, asthma, anemia, and cancer. Targeting CISH enhances the efficacy of adoptive T-cell and NK cell therapies against tumors.
Inhibition of CISH enhances T cell and NK cell activity against tumors. Targeting CISH in NK cells improves ex vivo proliferation and limits NK cell exhaustion, impairing primary tumor and metastasis development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytokine-inducible SH2-containing protein (CISH).